CRESCENT BIOPHARMA, INC. financial data

Symbol
CBIO on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 669% % 19%
Debt-to-equity 43% % 76%
Return On Equity -145% % -213%
Return On Assets -90% % -171%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,892,516 shares -78%
Common Stock, Shares, Outstanding 13,892,516 shares -78%
Entity Public Float $17,500,000 USD -84%
Common Stock, Value, Issued $14,000 USD -78%
Weighted Average Number of Shares Outstanding, Basic 64,522,257 shares 0.1%
Weighted Average Number of Shares Outstanding, Diluted 64,477,249 shares 1.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $31,918,337 USD 723%
General and Administrative Expense $25,800,892 USD 3405%
Operating Income (Loss) $65,249,533 USD -884%
Nonoperating Income (Expense) $1,409,465 USD 131%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $75,961,085 USD -835%
Earnings Per Share, Basic 0 USD/shares 21%
Earnings Per Share, Diluted 0 USD/shares -1.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $133,265,000 USD 826%
Assets, Current $134,563,000 USD 760%
Property, Plant and Equipment, Net $782,000 USD
Operating Lease, Right-of-Use Asset $1,564,000 USD
Other Assets, Noncurrent $1,253,000 USD
Assets $138,269,000 USD 781%
Accounts Payable, Current $104,671 USD -86%
Employee-related Liabilities, Current $2,751,000 USD
Accrued Liabilities, Current $8,965,000 USD 158%
Liabilities, Current $20,304,000 USD 370%
Operating Lease, Liability, Noncurrent $1,324,000 USD
Liabilities $21,628,000 USD 400%
Retained Earnings (Accumulated Deficit) $79,412,000 USD 84%
Stockholders' Equity Attributable to Parent $116,641,000 USD
Liabilities and Equity $138,269,000 USD 781%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,105,992 USD 51%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 175,000,000 shares 17%
Common Stock, Shares, Issued 13,892,516 shares -78%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,105,992 USD 51%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $133,372,000 USD
Deferred Tax Assets, Valuation Allowance $170,722,283 USD 5.8%
Deferred Tax Assets, Gross $170,722,283 USD 5.7%
Operating Lease, Liability $1,741,000 USD 564%
Depreciation $0 USD -100%
Payments to Acquire Property, Plant, and Equipment $0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $24,607,000 USD -835%
Lessee, Operating Lease, Liability, to be Paid $2,074,000 USD 675%
Operating Lease, Liability, Current $417,000 USD 59%
Lessee, Operating Lease, Liability, to be Paid, Year Two $608,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $584,000 USD 766%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $333,000 USD 5946%
Lessee, Operating Lease, Liability, to be Paid, Year Three $633,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $96,811,786 USD 9.1%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) $0 USD
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $107,000 USD
Operating Lease, Payments $660,270 USD -29%
Additional Paid in Capital $192,039,000 USD -61%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $9,959,572 USD 2777%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%